Described herein are methods for treating rheumatoid arthritis by determining whether a subject having rheumatoid arthritis will respond to an anti-TNF-alpha therapy based on the number of innate and adaptive immune cells in a sample from the subject prior to treatment.

The present invention provides biological markers which are molecular and cellular antecedents of rheumatoid arthritis (RA) flares. The invention provides RNA and protein markers that can predict an RA flare one or two weeks prior to the flare. The invention further provides blood circulating cells, particularly pre-inflammatory mesenchymal cells, which are cellular precursors and indicators of an impending RA flare. The present invention further provides methods, kits and markers for identification and monitoring of flares in RA patients and their application as markers and targets in and for treatment of rheumatoid arthritis and conditions induced or related to rheumatoid arthritis.

Uses and a composition including a peptidylarginine deiminase 2 (PADI2) as an active ingredient are disclosed. A peptidylarginine deiminase 2 (PADI2) is useful for preventing or alleviating cellular senescence.

The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).

Methods and kits for diagnosing arthritis are provided. The methods may involve detection of 14-3-3 eta or gamma proteins in a sera or synovial fluid sample.

Biomarkers useful for diagnosing and assessing inflammatory disease are provided, along with kits for measuring their expression. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples. The biomarkers include at least two biomarkers selected from the DAIMRK group and the score is a disease activity index (DAI).

The present invention provides methods for differentially diagnosing rheumatoid arthritis (RA) versus psoriatic arthritis (PsA) in an individual. Specifically, the method relates to detecting the presence or absence of distinct alleles of the PDE4D and PDE4B genes which are associated with either RA or PsA. Also provided herein are methods for selecting an individual who should receive or who is likely to respond to a treatment with a PDE4 inhibitor. The present invention also provides methods for treating an individual with RA or PsA.

The present invention relates to a biomarker for diagnosing rheumatoid arthritis, a biomarker for diagnosing osteoporosis as a complication of rheumatoid arthritis, a biomarker for predicting the severity and prognosis of rheumatoid arthritis, and a use thereof.

The disclosure relates to biomarkers of rheumatoid arthritis, e.g., PTPN22, PFKFB3, ATM, IL-17A, and IL-17F, and methods of using these biomarkers for selecting an effective treatment for rheumatoid arthritis.

The present disclosure relates to the field of molecular biology and more specifically to methods for detecting anti-carbamylated protein (anti-CarP) antibodies in the serum of rheumatoid arthritis (RA) patients.